Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Mechanisms of Deregulation of Apoptosis in Myeloma

Simone Fulda, MD

Blood (2019) 134 (Supplement_1): SCI-10.

https://doi.org/10.1182/blood-2019-121102

Published: 2019

Journal Articles

Drug Design for Overcoming High-Risk Myeloma and Identification of Novel Binding Proteins to Immune-Modulatory Drugs

Masashi Hozumi, Daiju Ichikawa, PhD, Maiko Matsushita, MD PhD, Eriko Kamiyama, Hiroshi Yanagawa, PhD, Noriko Tabata, PhD, Shotaro Kitabatake, Arimi Ueda, Takashi Yamaguchi, Mariko Sato, Yutaka Hattori, MD PhD

Blood (2015) 126 (23): 1800.

https://doi.org/10.1182/blood.V126.23.1800.1800

Published: 2015

Journal Articles

Rational Drug Design: Proteasome Inhibitor Mediated Down-Regulation of the FA/BRCA Pathway Is Synergistic with PARP Inhibition in Myeloma Cell Lines

Liang Nong, M.D., Linda Mathews, Mark B Meads, Ph.D., William Dalton, PhD, MD, Kenneth H. Shain, MD, PhD

Blood (2011) 118 (21): 2922.

https://doi.org/10.1182/blood.V118.21.2922.2922

Published: 2011

Journal Articles

Structure-Based Drug Design of c-Kit Inhibitors for Use in the Treatment of Acute Myeloid Leukemia.

David S. Maxwell, PhD, Ashutosh Pal, Zhenghong Peng, Alexandr Shavrin, Stefan Faderl, MD, David Harris, Quin Van, Zhiming Liu, Srdan Verstovsek, MD PhD, Taghi Manshouri, MB BS, Alessandra Ferrajoli, MD, Hagop M. Kantarjian, MD, Zeev Estrov, MD, William G. Bornmann, PhD

Blood (2006) 108 (11): 1906.

https://doi.org/10.1182/blood.V108.11.1906.1906

Published: 2006

Journal Articles

Jak3 Kinase Domain Crystal Structures and Implications for Jak-Specific Drug Design.

Titus J. Boggon, PhD

Blood (2005) 106 (11): 69.

https://doi.org/10.1182/blood.V106.11.69.69

Published: 2005

Journal Articles

Egr-1 Abrogates the Block Imparted by c-Myc on Terminal M1 Myeloid Differentiation.

Barbara Hoffman, PhD, Marianna Shafarenko, PhD, Dan A. Liebermann, PhD

Blood (2004) 104 (11): 2579.

https://doi.org/10.1182/blood.V104.11.2579.2579

Published: 2004

Journal Articles

Molecular Models of the Procoagulant Intrinsic Tenase Complex.

L. Autin, W. H. Lee, M. A. Miteva, K. Mertens, K. P. Radtke, B. O. Villoutreix

Blood (2004) 104 (11): 1723.

https://doi.org/10.1182/blood.V104.11.1723.1723

Published: 2004

NARROW

Mechanisms of Deregulation of Apoptosis in Myeloma

Drug Design for Overcoming High-Risk Myeloma and Identification of Novel Binding Proteins to Immune-Modulatory Drugs

Rational Drug Design: Proteasome Inhibitor Mediated Down-Regulation of the FA/BRCA Pathway Is Synergistic with PARP Inhibition in Myeloma Cell Lines

Structure-Based Drug Design of c-Kit Inhibitors for Use in the Treatment of Acute Myeloid Leukemia.

Jak3 Kinase Domain Crystal Structures and Implications for Jak-Specific Drug Design.

Egr-1 Abrogates the Block Imparted by c-Myc on Terminal M1 Myeloid Differentiation.

Molecular Models of the Procoagulant Intrinsic Tenase Complex.

Email alerts

ASH Publications

American Society of Hematology

Mechanisms of Deregulation of Apoptosis in Myeloma

Drug Design for Overcoming High-Risk Myeloma and Identification of Novel Binding Proteins to Immune-Modulatory Drugs

Rational Drug Design: Proteasome Inhibitor Mediated Down-Regulation of the FA/BRCA Pathway Is Synergistic with PARP Inhibition in Myeloma Cell Lines

Structure-Based Drug Design of c-Kit Inhibitors for Use in the Treatment of Acute Myeloid Leukemia.

Jak3 Kinase Domain Crystal Structures and Implications for Jak-Specific Drug Design.

Egr-1 Abrogates the Block Imparted by c-Myc on Terminal M1 Myeloid Differentiation.

Molecular Models of the Procoagulant Intrinsic Tenase Complex.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only